A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
Condition(s):Primary Mitochondrial MyopathyLast Updated:January 24, 2022Terminated
Hide Studies Not Open or Pending
Condition(s):Primary Mitochondrial MyopathyLast Updated:January 24, 2022Terminated
Condition(s):Primary Mitochondrial MyopathiesLast Updated:March 3, 2023Recruiting
Condition(s):Primary Mitochondrial MyopathyLast Updated:July 16, 2020Terminated
Condition(s):Primary Mitochondrial MyopathyLast Updated:January 22, 2024Active, not recruiting
Condition(s):Primary Mitochondrial MyopathyLast Updated:February 9, 2024Terminated
Condition(s):Primary Mitochondrial MyopathyLast Updated:October 23, 2023Completed
Condition(s):Primary Mitochondrial DiseaseLast Updated:December 17, 2021Terminated
Condition(s):PolG, Primary Mitochondrial MyopathyLast Updated:December 22, 2023Recruiting
Condition(s):Primary Mitochondrial DiseaseLast Updated:July 17, 2020Completed
Condition(s):Mitochondrial Myopathies; Mitochondrial Pathology; Mitochondrial DNA Mutation; Mitochondrial Diseases; Mitochondrial DNA Deletion; Mitochondrial DNA Depletion; Mitochondrial Metabolism Defect; Mitochondrial Complex I DeficiencyLast Updated:December 12, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.